RxDoctor Payments Data

Syed Ghani, MD

Adolescent Medicine · McHenry, ILNPI 1205877396

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson at 25.8% of the total. That places this record below the midpoint for adolescent medicine clinicians in IL, where the typical reported total is $278.

$298in general payments, 2019–2025

Across 15 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$77
  • Novartis$48
  • Chiesi USA, Inc.$43
  • AbbVie$40
  • Boehringer Ingelheim$27
  • Boston Scientific$25
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$298 in reported general payments places this provider in the 50th percentile of 60 adolescent medicine providers in Illinois.

See all adolescent medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$237,424
Medicare patients
857
Services billed
2,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban405$128,599
XareltoRivaroxaban72$26,006
JardianceEmpagliflozin53$17,271
Tresiba Flextouch U-200Insulin Degludec21$13,607
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,288
TrulicityDulaglutide11$11,205
Potassium Chloride233$10,850
Breo ElliptaFluticasone/Vilanterol24$10,621
Gabapentin335$7,724
JanuviaSitagliptin Phosphate26$7,431
Incruse ElliptaUmeclidinium Bromide19$7,342
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$7,254
TradjentaLinagliptin25$6,805
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,718
Lantus SolostarInsulin Glargine,hum.Rec.Anlog129$6,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$27$29,74289 claims
Johnson & JohnsonXarelto$77$26,00672 claims
AbbVieCreon$40$5,52019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 60 adolescent medicine providers in Illinois.

Other adolescent medicine in McHenry

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →